Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACLX 
Arcellx Inc (ACLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ACLX (3-star) is a STRONG-BUY. BUY since 70 days. Simulated Profits (13.58%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $113.07
1 Year Target Price $113.07
| 12 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 52.3% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.23B USD | Price to earnings Ratio - | 1Y Target Price 113.07 |
Price to earnings Ratio - | 1Y Target Price 113.07 | ||
Volume (30-day avg) 18 | Beta 0.27 | 52 Weeks Range 47.86 - 107.37 | Updated Date 09/16/2025 |
52 Weeks Range 47.86 - 107.37 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -777.42% |
Management Effectiveness
Return on Assets (TTM) -19.8% | Return on Equity (TTM) -42.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3824824505 | Price to Sales(TTM) 74.16 |
Enterprise Value 3824824505 | Price to Sales(TTM) 74.16 | ||
Enterprise Value to Revenue 67.13 | Enterprise Value to EBITDA -6.52 | Shares Outstanding 55458900 | Shares Floating 37268389 |
Shares Outstanding 55458900 | Shares Floating 37268389 | ||
Percent Insiders 13.45 | Percent Institutions 106.11 |
Upturn AI SWOT
Arcellx Inc
Company Overview
History and Background
Arcellx, Inc. is a clinical-stage biotechnology company founded in 2015 and focused on developing adaptive and controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The company utilizes its ARC-SparX platform to create CAR-T therapies.
Core Business Areas
- Cell Therapy Development: Arcellx focuses on developing and commercializing cell therapies, primarily using its ARC-SparX platform. Their lead product candidates target hematologic cancers, including multiple myeloma.
- Platform Technology: The ARC-SparX platform is a differentiating technology that allows for controllable activity of CAR-T cells, enhancing safety and efficacy.
Leadership and Structure
Arcellx is led by a management team with experience in cell therapy development and commercialization. The organizational structure supports research, clinical development, and manufacturing operations.
Top Products and Market Share
Key Offerings
- Cartitude-Arca (idecabtagene vrcell-arcsparx): Arcellx's lead product candidate for relapsed or refractory multiple myeloma. In competition with products like Abecma (idecabtagene vicleucel) from BMS and KarMMa-3 approved in March 2024, sales expectations have not yet been published.
- ACLX-001: Therapeutic candidate for acute myeloid leukemia, also utilizing the ARC-SparX platform. This product is in early clinical development. Competitors include marketed AML therapies and other investigational AML treatments.
Market Dynamics
Industry Overview
The cell therapy market is a rapidly growing segment of the biotechnology industry, driven by advancements in immunotherapy and personalized medicine. It addresses unmet needs in cancer treatment and other diseases.
Positioning
Arcellx is positioned as an innovator in the cell therapy space, differentiating itself through its ARC-SparX platform, which aims to improve the safety and efficacy of CAR-T therapies.
Total Addressable Market (TAM)
The total addressable market for CAR-T cell therapies is expected to grow to tens of billions of dollars in the coming years. Arcellx is targeting specific segments within this market, such as multiple myeloma and AML.
Upturn SWOT Analysis
Strengths
- Proprietary ARC-SparX platform technology
- Promising clinical data for lead product candidate
- Experienced management team
- Strong IP position
Weaknesses
- Clinical stage company with no approved products
- Reliance on successful clinical development
- High development costs
- Intense competition in the cell therapy space
Opportunities
- Potential to address unmet needs in cancer treatment
- Expansion of ARC-SparX platform to other indications
- Partnerships with larger pharmaceutical companies
- Regulatory approvals and commercialization
Threats
- Clinical trial failures
- Competition from established cell therapy companies
- Regulatory hurdles
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- BMY
- JNJ
- GILD
Competitive Landscape
Arcellx's ARC-SparX platform offers a potential advantage in safety and efficacy compared to existing CAR-T therapies. However, they face competition from established players with approved products and significant resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires data from past SEC filings.
Future Projections: Future projections are based on analyst estimates, which are dynamic and subject to change.
Recent Initiatives: Recent initiatives include progressing clinical trials for lead product candidates and expanding the ARC-SparX platform.
Summary
Arcellx is a clinical-stage biotech company with a promising ARC-SparX platform for cell therapies. Its lead candidate targets multiple myeloma, facing competition in a growing market. Successful clinical trials and commercialization are crucial for its growth, but it faces development and competitive risks. The company must look out for how the Phase 3 Cartitude-Arca readout may change how the analysts see this stock.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcellx Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcellx Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2022-02-04 | Chairman of the Board, CEO & President Mr. Rami Elghandour | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.arcellx.com |
Full time employees 163 | Website https://www.arcellx.com | ||
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.